These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21931037)

  • 21. Evaluation of direct medical costs of hospitalization for febrile neutropenia.
    Lathia N; Mittmann N; DeAngelis C; Knowles S; Cheung M; Piliotis E; Shear N; Walker S
    Cancer; 2010 Feb; 116(3):742-8. PubMed ID: 20029970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized placebo-controlled trial of oral antibiotics in pediatric oncology patients at low-risk with fever and neutropenia.
    Klaassen RJ; Allen U; Doyle JJ
    J Pediatr Hematol Oncol; 2000; 22(5):405-11. PubMed ID: 11037850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial.
    García-Carbonero R; Mayordomo JI; Tornamira MV; López-Brea M; Rueda A; Guillem V; Arcediano A; Yubero A; Ribera F; Gómez C; Trés A; Pérez-Gracia JL; Lumbreras C; Hornedo J; Cortés-Funes H; Paz-Ares L
    J Natl Cancer Inst; 2001 Jan; 93(1):31-8. PubMed ID: 11136839
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.
    Rivas-Ruiz R; Villasis-Keever M; Miranda-Novales G; Castelán-Martínez OD; Rivas-Contreras S
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD009031. PubMed ID: 30887505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new ciprofloxacin stepdown program in the treatment of high-risk febrile neutropenia: a clinical and economic analysis.
    Marra CA; Frighetto L; Quaia CB; de Lemos ML; Warkentin DI; Marra F; Jewesson PJ
    Pharmacotherapy; 2000 Aug; 20(8):931-40. PubMed ID: 10939554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs associated with febrile neutropenia in the US.
    Michels SL; Barron RL; Reynolds MW; Smoyer Tomic K; Yu J; Lyman GH
    Pharmacoeconomics; 2012 Sep; 30(9):809-23. PubMed ID: 22804805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and costs of treating neutropenic fever in an outpatient setting.
    Del Prete SA; Ryan SP; Jacobson JS; Erichson RB; Weinstein PL; Grann VR
    Conn Med; 1999 Dec; 63(12):713-7. PubMed ID: 10659471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [An organizational and economic approach in France to the ambulatory treatment of febrile neutropenia].
    Turlure P; Durand-Zaleski I
    Presse Med; 2004 Mar; 33(5):338-42. PubMed ID: 15041886
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost analysis of febrile neutropenia management in Australia: ambulatory v. in-hospital treatment.
    Lingaratnam S; Worth LJ; Slavin MA; Bennett CA; Kirsa SW; Seymour JF; Dalton A; Koczwara B; Prince HM; O'Reilly M; Mileshkin L; Szer J; Thursky KA
    Aust Health Rev; 2011 Nov; 35(4):491-500. PubMed ID: 22126955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences.
    Sung L; Feldman BM; Schwamborn G; Paczesny D; Cochrane A; Greenberg ML; Maloney AM; Hendershot EI; Naqvi A; Barrera M; Llewellyn-Thomas HA
    J Clin Oncol; 2004 Oct; 22(19):3922-9. PubMed ID: 15459214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
    Courtney DM; Aldeen AZ; Gorman SM; Handler JA; Trifilio SM; Parada JP; Yarnold PR; Bennett CL
    Oncologist; 2007 Aug; 12(8):1019-26. PubMed ID: 17766662
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The costs of treating febrile neutropenia in patients with malignant blood disorders.
    Leese B; Collin R; Clark DJ
    Pharmacoeconomics; 1994 Sep; 6(3):233-9. PubMed ID: 10155266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of step-down to oral outpatient treatment versus inpatient antimicrobial treatment in pediatric cancer patients with febrile neutropenia: A noninferiority multicenter randomized clinical trial.
    Avilés-Robles MJ; Reyes-López A; Otero-Mendoza FJ; Valencia-Garin AU; Peñaloza-González JG; Rosales-Uribe RE; Muñoz-Hernández O; Garduño-Espinosa J; Juárez-Villegas L; Zapata-Tarrés M
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28251. PubMed ID: 32196898
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients.
    Calhoun EA; Chang CH; Welshman EE; Fishman DA; Lurain JR; Bennett CL
    Oncologist; 2001; 6(5):441-5. PubMed ID: 11675522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia.
    Elting LS; Lu C; Escalante CP; Giordano SH; Trent JC; Cooksley C; Avritscher EB; Shih YC; Ensor J; Bekele BN; Gralla RJ; Talcott JA; Rolston K
    J Clin Oncol; 2008 Feb; 26(4):606-11. PubMed ID: 18235119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.
    Tai E; Guy GP; Dunbar A; Richardson LC
    J Oncol Pract; 2017 Jun; 13(6):e552-e561. PubMed ID: 28437150
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The economics of febrile neutropenia: implications for the use of colony-stimulating factors.
    Lyman GH; Kuderer N; Greene J; Balducci L
    Eur J Cancer; 1998 Nov; 34(12):1857-64. PubMed ID: 10023306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ciprofloxacin and amoxicillin as continuation treatment of febrile neutropenia in pediatric cancer patients.
    Park JR; Coughlin J; Hawkins D; Friedman DL; Burns JL; Pendergrass T
    Med Pediatr Oncol; 2003 Feb; 40(2):93-8. PubMed ID: 12461792
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
    Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
    Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.